一种新的药物大大扩展了肺癌患者对抗标准治疗的存活期。 A new drug significantly extended survival for lung cancer patients resistant to standard treatment.

一项第三期试验,OptiTROP- Lung04,发现sac- TMT,一种TROP2- 向抗体- 药物联体,在EGFR突变非小细胞肺癌患者中显著改善了无进展生存率和整体生存率,这些患者在EGFR- TKI治疗后已经进展. A Phase 3 trial, OptiTROP-Lung04, found that sacituzumab tirumotecan (sac-TMT), a TROP2-targeted antibody-drug conjugate, significantly improved progression-free survival and overall survival in patients with EGFR-mutated non-small cell lung cancer who had progressed after EGFR-TKI therapy. 在376名病人中, sac-TMT将PFS中位数延长到8.3个月,而化疗为4.3个月,使疾病增加或死亡减少了51%。 Among 376 patients, sac-TMT extended median PFS to 8.3 months versus 4.3 months for chemotherapy, reducing disease progression or death by 51%. 临时总体生存数据表明,在接受化疗17.4个月之后,沙子-TMT没有达到中位数,而接受化疗的中位数则降低40%的死亡风险。 Interim overall survival data showed a median not reached with sac-TMT versus 17.4 months with chemotherapy, a 40% lower risk of death. 各分组的效益一致,答复率更高,安全情况可管理。 Benefits were consistent across subgroups, with higher response rates and a manageable safety profile. 中国已经针对几种癌症类型批准使用该药物,并正在对此进行审查,以了解更多迹象。 The drug is already approved in China for several cancer types and is under review for additional indications.